Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 388-397

  Brass, Clifford A ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chronic hepatitis C infection; Consensus interferon; Interferon alfa 2b; Nonresponse; Relapse; Retreatment

Indexed keywords

ALPHA2B INTERFERON; INTERFERON;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; RELAPSE; REVIEW; VIRUS DETECTION;

EID: 0031878885     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80050-7     Document Type: Review

References (19)

1. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
2. Infergen® (Interferon alfacon-1) prescribing information. Amgen Inc., Thousand Oaks, Calif; 1997.
3. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology. 1997;26(Suppl 1):2S-10S.
4. Alberti A, Chemello L, Noventa F, et al. Therapy of hepatitis C: Re-treatment with alpha Interferon. Hepatology. 1997;26 (Suppl 1):137S-142S.
5. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology. 1996;24:778-789.
6. Davis GL, Beck JR, Farrell G, Poynard T. Prolonged course versus 6-months of interferon alfa or no treatment in patients with histologically mild chronic hepatitis C: A decision analysis. Gastroenterology. 1997;112(Suppl):A1252. Abstract.
7. Payen JL, Izopet J, Galindo V, et al. A comparison of three interferon alfa-2b regimens for retreatment (RTT) of patients with chronic hepatitis C with prior complete response followed by relapse: A controlled, randomized trial. Hepatology. 1996;24:273A. Abstract.
8. Le X, Zhou X, Dai X. Evaluation of interferon-α2b for the treatment of relapsed hepatitis C. Hepatology. 1996;24:536A. Abstract.
9. Fuschi P, Almasio P, Di Marco V, et al. Should patients with chronic hepatitis C who relapse after interferon (IFN) be retreated? J Hepatol. 1997;26(Suppl):192. Abstract.
10. Picciotto A, Sinelli N, Brizzolara R, et al. Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C. J Hepatol. 1997;26:447-448. Letter.
11. Tong M, Blatt LM, Tong L, et al. Retreatment of chronic HCV patients who previously failed 24 weeks of interferon alfa 2b with longer duration therapy. Hepatology. 1997;26:418A. Abstract.
12. Marcellin P, Boyer N, Pouteau M, et al. Retreatment with interferon-α of chronic hepatitis C virus infection. Lancet. 1994; 344:690-691.
13. Giudici-Cipriani A, Azzola E, Varagona G, et al. Usefulness of re-treatment with interferon (IFN) in relapsing and non-responder patients with chronic hepatitis C. J Hepatol. 1993;18(Suppl 1):S123-S124. Abstract.
14. Keeffe EB, Hollinger FB, and the Consensus Interferon Study Group. Therapy of hepatitis C: Consensus interferon trials. Hepatology. 1997;26(Suppl 1):101S-107S.
15. Kawanishi H. A therapeutic trial of higher dosing regimen of alpha (α) interferon (IFN) monitored by serum HCV-RNA levels for patients with chronic hepatitis (CH) C, who failed the treatment with 3 MU standard dose of αIFN. Hepatology. 1995;22(Suppl 1):437A. Abstract.
16. Rolachon A, Kézachian G, Causse X, et al. Interest of a higher dose of interferon alpha in non responder patients with chronic hepatitis C: A prospective randomized study. Hepatology. 1996;24 (Suppl):569A. Abstract.
17. Adams G, Casey DL, Trivedi M, et al. High dose induction therapy with interferon alfa 2b for chronic hepatitis C patients unresponsive to conventional therapy. Hepatology. 1996;24(Suppl):273A. Abstract.
18. Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. J Hepatol. 1995;23:487-496.
19. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. NEJM. 1995;332:1458-1462.